Is STTK or RNA more profitable?

Avidity Biosciences' return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Avidity Biosciences N/A N/A N/A

Does the media prefer STTK or RNA?

In the previous week, Shattuck Labs and Shattuck Labs both had 3 articles in the media. Shattuck Labs' average media sentiment score of 0.78 beat Avidity Biosciences' score of 0.49 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RNA or CTMX?

In the previous week, CytomX Therapeutics had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 6 mentions for CytomX Therapeutics and 3 mentions for Avidity Biosciences. CytomX Therapeutics' average media sentiment score of 0.65 beat Avidity Biosciences' score of 0.49 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is RNA or ALLO more profitable?

Avidity Biosciences' return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avidity Biosciences N/A N/A N/A Allogene Therapeutics N/A -50.04% -36.74%

Does the media favor RNA or ALLO?

In the previous week, Avidity Biosciences had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for Avidity Biosciences and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.91 beat Avidity Biosciences' score of 0.49 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RNA or PROK more profitable?

Avidity Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. Company Net Margins Return on Equity Return on Assets Avidity Biosciences N/A N/A N/A ProKidney -10,288.39% N/A -27.39%

Does the media refer more to RNA or PROK?

In the previous week, Avidity Biosciences had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Avidity Biosciences and 2 mentions for ProKidney. ProKidney's average media sentiment score of 1.23 beat Avidity Biosciences' score of 0.49 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RNA or PRME?

In the previous week, Prime Medicine had 12 more articles in the media than Avidity Biosciences. MarketBeat recorded 15 mentions for Prime Medicine and 3 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.49 beat Prime Medicine's score of 0.36 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 2 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Avidity Biosciences (RNA) Competitors

$8.29 +0.10 (+1.22%)

As of 09/25/2026 04:00 PM Eastern

Compare

RNA vs. STTK, CTMX, ALLO, PROK, and PRME

Should you buy Avidity Biosciences stock or one of its competitors? Avidity Biosciences's main competitors and comparable companies include Shattuck Labs (STTK), CytomX Therapeutics (CTMX), Allogene Therapeutics (ALLO), ProKidney (PROK), and Prime Medicine (PRME). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avidity Biosciences compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Avidity Biosciences' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Avidity Biosciences	N/A	N/A	N/A

Avidity Biosciences has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	609.20	-$48.81M	-$0.51	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

In the previous week, Shattuck Labs and Shattuck Labs both had 3 articles in the media. Shattuck Labs' average media sentiment score of 0.78 beat Avidity Biosciences' score of 0.49 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Shattuck Labs currently has a consensus target price of $12.78, suggesting a potential upside of 110.51%. Avidity Biosciences has a consensus target price of $63.75, suggesting a potential upside of 669.00%. Given Avidity Biosciences' higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25

Summary

Shattuck Labs beats Avidity Biosciences on 8 of the 12 factors compared between the two stocks.

How does Avidity Biosciences compare to CytomX Therapeutics?

Avidity Biosciences (NASDAQ:RNA) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

67.8% of CytomX Therapeutics shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Avidity Biosciences presently has a consensus target price of $63.75, suggesting a potential upside of 669.00%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 340.74%. Given Avidity Biosciences' higher probable upside, equities analysts clearly believe Avidity Biosciences is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, CytomX Therapeutics had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 6 mentions for CytomX Therapeutics and 3 mentions for Avidity Biosciences. CytomX Therapeutics' average media sentiment score of 0.65 beat Avidity Biosciences' score of 0.49 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Avidity Biosciences has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. Avidity Biosciences' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Avidity Biosciences has higher earnings, but lower revenue than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A
CytomX Therapeutics	$76.20M	7.72	-$17.37M	-$0.50	N/A

Summary

CytomX Therapeutics beats Avidity Biosciences on 7 of the 13 factors compared between the two stocks.

How does Avidity Biosciences compare to Allogene Therapeutics?

Avidity Biosciences (NASDAQ:RNA) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

In the previous week, Avidity Biosciences had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for Avidity Biosciences and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.91 beat Avidity Biosciences' score of 0.49 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avidity Biosciences has higher earnings, but lower revenue than Allogene Therapeutics. Avidity Biosciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A
Allogene Therapeutics	$4.64M	122.86	-$190.89M	-$0.67	N/A

83.6% of Allogene Therapeutics shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Avidity Biosciences' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
Allogene Therapeutics	N/A	-50.04%	-36.74%

Avidity Biosciences currently has a consensus target price of $63.75, indicating a potential upside of 669.00%. Allogene Therapeutics has a consensus target price of $8.30, indicating a potential upside of 403.03%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

Allogene Therapeutics beats Avidity Biosciences on 8 of the 12 factors compared between the two stocks.

How does Avidity Biosciences compare to ProKidney?

Avidity Biosciences (NASDAQ:RNA) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

51.6% of ProKidney shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Avidity Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
ProKidney	-10,288.39%	N/A	-27.39%

Avidity Biosciences currently has a consensus target price of $63.75, suggesting a potential upside of 669.00%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 650.00%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Avidity Biosciences has higher earnings, but lower revenue than ProKidney. Avidity Biosciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A
ProKidney	$818K	591.34	-$68.99M	-$0.55	N/A

In the previous week, Avidity Biosciences had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Avidity Biosciences and 2 mentions for ProKidney. ProKidney's average media sentiment score of 1.23 beat Avidity Biosciences' score of 0.49 indicating that ProKidney is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ProKidney beats Avidity Biosciences on 7 of the 12 factors compared between the two stocks.

How does Avidity Biosciences compare to Prime Medicine?

Avidity Biosciences (NASDAQ:RNA) and Prime Medicine (NASDAQ:PRME) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Avidity Biosciences has higher earnings, but lower revenue than Prime Medicine. Avidity Biosciences is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A
Prime Medicine	$4.07M	129.14	-$201.14M	-$1.06	N/A

70.4% of Prime Medicine shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Prime Medicine had 12 more articles in the media than Avidity Biosciences. MarketBeat recorded 15 mentions for Prime Medicine and 3 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.49 beat Prime Medicine's score of 0.36 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	2 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avidity Biosciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Avidity Biosciences' return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
Prime Medicine	-4,613.11%	-188.27%	-59.11%

Avidity Biosciences presently has a consensus target price of $63.75, indicating a potential upside of 669.00%. Prime Medicine has a consensus target price of $7.47, indicating a potential upside of 157.66%. Given Avidity Biosciences' higher probable upside, research analysts plainly believe Avidity Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Prime Medicine beats Avidity Biosciences on 8 of the 13 factors compared between the two stocks.

Get Avidity Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNA vs. The Competition

Export

Metric	Avidity Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$141.81M	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-3.86	14.15	275.82	25.78
Price / Sales	N/A	1,442.79	650.06	92.83
Price / Cash	N/A	120.91	79.52	52.89
Price / Book	N/A	15.28	10.44	6.30
Net Income	N/A	-$22.90M	$3.51B	$360.35M
7 Day Performance	-7.37%	-2.94%	-1.31%	-0.23%
1 Month Performance	-40.70%	-8.80%	-4.61%	-4.16%
1 Year Performance	-80.70%	28.99%	15.01%	4.58%

Avidity Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNA Avidity Biosciences	1.5176 of 5 stars	$8.29 +1.2%	$63.75 +669.0%	-80.7%	$141.81M	N/A	N/A	190
STTK Shattuck Labs	2.962 of 5 stars	$6.11 +1.7%	$12.78 +109.1%	+166.2%	$603.18M	$1M	N/A	40
CTMX CytomX Therapeutics	2.2083 of 5 stars	$2.76 flat	$11.90 +331.2%	-6.9%	$601.40M	$76.20M	N/A	69	News Coverage
ALLO Allogene Therapeutics	2.2235 of 5 stars	$1.69 flat	$8.30 +391.1%	+32.0%	$583.88M	$20K	N/A	152	Positive News Analyst Upgrade
PROK ProKidney	1.8194 of 5 stars	$1.78 -7.1%	$12.00 +576.1%	-35.7%	$577.44M	$890K	N/A	231

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNA) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avidity Biosciences (RNA) Competitors

RNA vs. STTK, CTMX, ALLO, PROK, and PRME

How does Avidity Biosciences compare to Shattuck Labs?

Summary

How does Avidity Biosciences compare to CytomX Therapeutics?

Summary

How does Avidity Biosciences compare to Allogene Therapeutics?

Summary

How does Avidity Biosciences compare to ProKidney?

Summary

How does Avidity Biosciences compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avidity Biosciences (RNA) Competitors

RNA vs. STTK, CTMX, ALLO, PROK, and PRME

How does Avidity Biosciences compare to Shattuck Labs?

Do institutionals & insiders hold more shares of STTK or RNA?

Is STTK or RNA more profitable?

Which has stronger earnings & valuation, STTK or RNA?

Does the media prefer STTK or RNA?

Do analysts prefer STTK or RNA?

Summary

How does Avidity Biosciences compare to CytomX Therapeutics?

Do institutionals and insiders have more ownership in RNA or CTMX?

Do analysts recommend RNA or CTMX?

Does the media favor RNA or CTMX?

Is RNA or CTMX more profitable?

Which has better earnings and valuation, RNA or CTMX?

Summary

How does Avidity Biosciences compare to Allogene Therapeutics?

Does the media favor RNA or ALLO?

Which has stronger valuation and earnings, RNA or ALLO?

Do insiders and institutionals have more ownership in RNA or ALLO?

Is RNA or ALLO more profitable?

Do analysts prefer RNA or ALLO?

Summary

How does Avidity Biosciences compare to ProKidney?

Do insiders & institutionals hold more shares of RNA or PROK?

Is RNA or PROK more profitable?

Do analysts rate RNA or PROK?

Which has better valuation & earnings, RNA or PROK?

Does the media refer more to RNA or PROK?

Summary

How does Avidity Biosciences compare to Prime Medicine?

Which has better earnings & valuation, RNA or PRME?

Do institutionals & insiders believe in RNA or PRME?

Does the media refer more to RNA or PRME?

Is RNA or PRME more profitable?

Do analysts recommend RNA or PRME?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools